Discounted Cash Flow (DCF) Analysis Levered

Anixa Biosciences, Inc. (ANIX)

$4.94

+0.05 (+1.02%)
All numbers are in Millions, Currency in USD
Stock DCF: -25.30 | 4.94 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.361.110.250.410.681.121.843.034.998.21
Revenue (%)
Operating Cash Flow -3.80-4.27-4.740.04-4.94-9.04-14.88-24.51-40.36-66.47
Operating Cash Flow (%)
Capital Expenditure -0.03-0.04-0.18-0.02-0.15-0.24-0.39-0.65-1.07-1.76
Capital Expenditure (%)
Free Cash Flow -3.83-4.31-4.920.02-5.08-9.28-15.28-25.16-41.43-68.23

Weighted Average Cost Of Capital

Share price $ 4.94
Beta 1.142
Diluted Shares Outstanding 28.58
Cost of Debt
Tax Rate 1.32
After-tax Cost of Debt 4.93%
Risk-Free Rate
Market Risk Premium
Cost of Equity 9.082
Total Debt 0.26
Total Equity 141.18
Total Capital 141.44
Debt Weighting 0.18
Equity Weighting 99.82
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.361.110.250.410.681.121.843.034.998.21
Operating Cash Flow -3.80-4.27-4.740.04-4.94-9.04-14.88-24.51-40.36-66.47
Capital Expenditure -0.03-0.04-0.18-0.02-0.15-0.24-0.39-0.65-1.07-1.76
Free Cash Flow -3.83-4.31-4.920.02-5.08-9.28-15.28-25.16-41.43-68.23
WACC
PV LFCF 0.03-5.08-8.50-12.84-19.39-29.28-44.20
SUM PV LFCF -114.21

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 9.07
Free cash flow (t + 1) -69.59
Terminal Value -984.36
Present Value of Terminal Value -637.72

Intrinsic Value

Enterprise Value -751.93
Net Debt -28.87
Equity Value -723.06
Shares Outstanding 28.58
Equity Value Per Share -25.30